Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study

Larimar Therapeutics (NASDAQ: LRMR) shares dropped 23.75% following the release of long-term open-label study data for its Friedreich’s ataxia treatment, nomlabofusp. While the study showed positive trends in mFARS scores and other clinical outcomes compared to a reference population, seven participants experienced anaphylaxis, prompting the company to implement a modified starting dose regimen. Despite these safety events, Larimar confirmed its marketing application submission for potential accelerated approval remains on track for Q2 2026.

Analysis

Larimar Therapeutics' stock plummeted 23.75% following the release of long-term data for its Friedreich’s ataxia (FA) drug, nomlabofusp, as significant safety concerns overshadowed promising efficacy signals. The primary driver of the negative market reaction was the report of seven study participants experiencing anaphylaxis, a serious adverse event that led to their withdrawal. While all affected individuals recovered, this safety signal has prompted the company to modify its starting dose regimen to a more cautious, tiered approach. In contrast to these safety issues, the study demonstrated positive efficacy trends, most notably a median improvement of 2.25 in the mFARS score at one year, compared to a 1.00 worsening observed in the FACOMS reference population. Despite the clear safety hurdles and resulting stock decline, Larimar management has reaffirmed its timeline to submit a marketing application for potential accelerated approval in the second quarter of 2026, indicating confidence that the new dosing strategy will be sufficient to manage the risk profile and satisfy regulatory bodies.

Key Decisions for Investors

• Investors must weigh the significant safety risk highlighted by the seven anaphylaxis events against the drug's demonstrated efficacy, as the market's 23.75% sell-off indicates a strong risk-averse sentiment.
• The success of the newly proposed modified dosing regimen is now the critical variable; its ability to mitigate safety concerns will be the primary determinant of the drug's future regulatory and commercial viability.
• For investors with a high risk tolerance, the sharp valuation reset could represent a buying opportunity, contingent on the belief that the efficacy data is compelling enough and the new dosing protocol will be acceptable to the FDA, especially given the reaffirmed Q2 2026 submission target.